Switch theme
Sign up to access all valuation multiples
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
1992
748
LTM Revenue $287M
LTM EBITDA $7.7M
$375M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AngioDynamics has a last 12-month revenue (LTM) of $287M and a last 12-month EBITDA of $7.7M.
In the most recent fiscal year, AngioDynamics achieved revenue of $304M and an EBITDA of -$6.1M.
AngioDynamics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AngioDynamics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $287M | XXX | $304M | XXX | XXX | XXX |
| Gross Profit | $154M | XXX | $155M | XXX | XXX | XXX |
| Gross Margin | 54% | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $7.7M | XXX | -$6.1M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | -2% | XXX | XXX | XXX |
| EBIT | -$35.7M | XXX | -$33.8M | XXX | XXX | XXX |
| EBIT Margin | -12% | XXX | -11% | XXX | XXX | XXX |
| Net Profit | -$12.7M | XXX | -$184M | XXX | XXX | XXX |
| Net Margin | -4% | XXX | -61% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AngioDynamics's stock price is $10.
AngioDynamics has current market cap of $415M, and EV of $375M.
See AngioDynamics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $375M | $415M | XXX | XXX | XXX | XXX | $-0.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AngioDynamics has market cap of $415M and EV of $375M.
AngioDynamics's trades at 1.3x EV/Revenue multiple, and 193.5x EV/EBITDA.
Equity research analysts estimate AngioDynamics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AngioDynamics has a P/E ratio of -32.6x.
See valuation multiples for AngioDynamics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $415M | XXX | $415M | XXX | XXX | XXX |
| EV (current) | $375M | XXX | $375M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 48.7x | XXX | 193.5x | XXX | XXX | XXX |
| EV/EBIT | -10.5x | XXX | -10.7x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -32.6x | XXX | -4.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -17.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAngioDynamics's last 12 month revenue growth is 6%
AngioDynamics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
AngioDynamics's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AngioDynamics's rule of X is 19% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AngioDynamics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Growth | 47% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 2% | XXX | 7% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 19% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AngioDynamics acquired XXX companies to date.
Last acquisition by AngioDynamics was XXXXXXXX, XXXXX XXXXX XXXXXX . AngioDynamics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AngioDynamics founded? | AngioDynamics was founded in 1992. |
| Where is AngioDynamics headquartered? | AngioDynamics is headquartered in United States of America. |
| How many employees does AngioDynamics have? | As of today, AngioDynamics has 748 employees. |
| Who is the CEO of AngioDynamics? | AngioDynamics's CEO is Mr. James C. Clemmer. |
| Is AngioDynamics publicy listed? | Yes, AngioDynamics is a public company listed on NAS. |
| What is the stock symbol of AngioDynamics? | AngioDynamics trades under ANGO ticker. |
| When did AngioDynamics go public? | AngioDynamics went public in 2004. |
| Who are competitors of AngioDynamics? | Similar companies to AngioDynamics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of AngioDynamics? | AngioDynamics's current market cap is $415M |
| What is the current revenue of AngioDynamics? | AngioDynamics's last 12 months revenue is $287M. |
| What is the current revenue growth of AngioDynamics? | AngioDynamics revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of AngioDynamics? | Current revenue multiple of AngioDynamics is 1.3x. |
| Is AngioDynamics profitable? | Yes, AngioDynamics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AngioDynamics? | AngioDynamics's last 12 months EBITDA is $7.7M. |
| What is AngioDynamics's EBITDA margin? | AngioDynamics's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of AngioDynamics? | Current EBITDA multiple of AngioDynamics is 48.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
